This is the authors' abstract. We don't add key points for this paper.
Background: Study 041 (NCT03179631) is an international, phase 3, randomized, double-blind, placebo-controlled 72-week Ataluren trial in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) followed by a 72-week open-label period. We describe results of a pooled analysis of Ataluren muscle function efficacy from the placebo-controlled phase of Study 041 and two previous randomized, placebo-controlled, 48-week Ataluren trials (Study 007 [phase 2b] and Study 020 [phase 3]). Methods: Patients were included in the studies if they were male, had phenotypic evidence of DMD-based characteristic clinical signs or symptoms, and an nmDMD diagnosis confirmed by genetic testing. Patients were randomized 1:1 to Ataluren:placebo. Efficacy was assessed by 48-week change in 6-minute walk distance (6MWD), North Star Ambulatory Assessment (NSAA) total and linear scores (where available), and timed function tests (TFTs; 10-m walk/run, 4-stair ascent, and 4-stair descent). In addition, 48-week change in 6MWD was assessed for a subgroup of patients with baseline 6MWD 300 to 400 m. Results: The overall pooled study population included 354 and 347 patients receiving Ataluren and placebo, respectively. Ataluren treatment significantly reduced mean change from baseline in all measures versus placebo (6MWD: 19.3 m, p = 0.0002; NSAA total score: 1.07, p = 0.0010; NSAA linear score: 2.70, p = 0.0031; 10 m walk/run time: −1.31 s, p = 0.0001; 4-stair ascent time: −1.45 s, p = 0.0003; 4-stair descent time: −1.54 s, p = 0.0003). The pooled subgroup with baseline 6 MWD 300 to 400 m included 155 and 157 patients receiving Ataluren and placebo, respectively. Ataluren preserved 32.1 m of 6MWD in this subgroup versus placebo ( p = 0.0005). Conclusion: Pooled randomized, placebo-controlled clinical trial data from 701 patients demonstrated that Ataluren preserved muscle function in patients with nmDMD. Publication History Article published online: 13 November 2023 © 2023. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
McDonald et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: